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Abstract 
 
Herpes simplex virus type 1 (HSV-1) infections are one of the most common diseases in human population. 
HSV-1 causes subclinical, mild to severe diseases, especially in immunocompromised patients. Acyclovir 
has been used to reduce manifestations of HSV-1 infections. The extensive use of this drug has led to the 
development of resistant strains. Thus, designing a novel anti-herpes drug with different mechanisms of 
action is urgently needed. Cellular microRNAs (miRNAs) have direct antiviral effects in addition to their 
regulatory functions. In this study we used a novel miRNA (hsa-miR-7704), expressed in macrophages, to 
inhibit HSV-1 lytic infection in HeLa cells. Synthesized hsa-miR-7704 mimics were transfected into HSV-1 
infected HeLa cell. The inhibitory effects of the miRNA were evaluated by plaque assay, real time 
polymerase chain reaction and the viral titers were measured by the 50% tissue culture infective dose 
(TCID50). The viral titer and cell cytopathic effect were dramatically decreased in HeLa cells transfected 
with hsa-miR-7704 (50 and 100 nM), compared with HSV-1 infected cells alone or transfected with the 
mock miRNA control. These results suggest that hsa-miR-7704 inhibits HSV-1 replication efficiently in 
vitro. This may provide an alternative mechanism to prevent HSV-1 infections. 
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INTRODUCTION 
 
Herpes simplex virus type 1 (HSV-1) is a 
linear double-stranded DNA and a neurotropic 
virus that infects mainly mucoepithelial cells. 
This virus belongs to the Herpesviridae family. 
HSV-1 establishes lifelong latency in the 
sensory ganglia (1). HSV-1 is a common 
communicable virus in human populations. In 
the Germany and United States, the prevalence 
of HSV-1 was approximately 50% and 75%, 
respectively (2,3). HSV-1 causes a wide range 
of diseases including stomatitis, encephalitis, 
and keratitis (4). the ability of the virus to 
spread to the central nervous system which 
leads to encephalitis, is the most serious 
complication of HSV-1 infection (5) Acyclovir 
and its derivatives have been used to reduce 
manifestations of HSV-1 infections (6). 
However, resistance to acyclovir is increasing 
in immunocompromised patients (7). This 
drug has serious side effects, especially in 
renal failure (8). Therefore, development of 
new anti-HSV-1 drugs is significant. 
MicroRNAs (miRNAs) are small,                 
non-coding RNAs that play a regulatory role 
in genes expression by binding to the target 
mRNA. It has been shown that miRNAs             
are involved in virus-host interactions.              
microRNA has been widely used to 
manipulate gene expression, identify gene 
functions on a whole-genome scale, and 
develop antiviral strategies for the prevention 
and treatment of human viral diseases (9). To 
date, miRNA has been employed against 
several human pathogens including hepatitis B 
and C virus (10, 11). 
 
 
 
 
 
 
Shabani et al. / RPS 2019; 14(2): 167-174 
 
168 
Increasing evidences have shown that 
interleukin-27 have antiviral effects against 
many viruses including HSV-1 (12). It has 
been reported that interleukin-27 differentiates 
monocytes to HIV-1, HIV-2, influenza, and 
simian immunodeficiency virus resistance 
macrophages (I-MAC). Investigation of 
miRNA expression profile in I-Mac revealed 
seven novel miRNA which are hsa-miR-7704 
(-SX1), -7705 (SX-2), -7702 (SX-3), -6852           
(-SX4), -SX-5, -7703 (-SX6), and -7706               
(-SX7). It seems that I-MAC induces antiviral 
effect presumably through miRNAs 
expression. Microarray analysis demonstrated 
that some of this miRNAs potentially target 
the open reading frame of the gene of HSV-1, 
poliovirus, HSV2, HIV-1 (13). This finding 
suggests that part of virus resistant feature of 
macrophages might be related to the presence 
of such novel miRNAs. microRNA mimics are 
innovative molecules designed to mimic 
endogenous mature miRNA molecules, when 
transfected into cells (14). 
In this study, we investigated the effect of 
overexpression of the novel hsa-miR-7704             
(-SX1) on HSV-1 replication using HeLa cells. 
Although the effect of lots of miRNAs on 
HSV-1 infection has been evaluated, the role 
of miR-SX1 on HSV-1 replication has 
remained uninvestigated. These findings may 
provide a new insight to miRNA-based 
antiviral therapy.  
 
MATERIAL AND METHOD 
 
Cell culture and virus 
HeLa cell line (ATCC CCL-2) was 
obtained from the National Cell Bank of Iran, 
Pasteur Institute of Iran (Tehran, I.R. Iran) and 
maintained in Dulbecco's modified eagle's 
medium (DMEM, Gibco, USA)-high glucose 
supplemented with 10% fetal calf serum  
(FCS; Gibco, USA), 100 units/mL penicillin, 
and 100 μg/mL streptomycin at 37 °C in               
5% CO2 (15). The HSV-1 strain was kindly 
provided from Virology Department,                  
Iran University of Medical Sciences,             
Tehran, I.R. Iran. The HSV-1 stock was 
propagated on HeLa cells, titrated by                 
50% tissue culture infective dose (TCID50) 
(16) and stored at -80 °C. 
Cytotoxicity assay 
Cytotoxicity of miR-SX-1 on HeLa cells 
was determined using 3- (4,5-dimethyl-                  
2-thiazolyl) - 2,5-diphenyl - 2H - tetrazolium 
bromide (MTT) assays (17). HeLa cells              
(15 × 104/well) were plated in 96-well plates. 
Cells were transfected with different 
concentrations of miRNA (50 and 100 nM) by 
polyfect (Qiagen, USA) according to the 
manufacturer’s instruction and incubated for 
24 h. Each transfection experiment was done 
in triplicate. After predetermined time, 10 µL 
MTT stock solution (5 mg/mL) was added to 
each well, and the plate was incubated for 4 h 
in the dark. Then, the MTT solution was 
discarded and 100 µL dimethyl sulfoxide 
(DMSO) was added to each well, and plates 
were gently shaken for 15 min at room 
temperature. The viability of cells was 
recorded at an absorbance of 570 and the 
reference wavelength of 630 nm by ELISA 
reader (BioRad, USA). The percentage of cell 
viability of each group was calculated by the 
following equation (17): 
Cell viability = (Absorbance of transfected cell/ 
Absorbance of control cells) × 100 
HSV-1 miR-SX1 mimics and transfection 
The miR-SX-1 mimics used in this 
experiment, are double-stranded and 
chemically synthesized by Qiagen (USA) 
according to the mature nucleotide sequences of 
miR-has-7704 obtained from www.mirbase.org 
as 5′- CGGGGUCGGCGGCGACGUG -
3′(accession number MIMAT0030019). The 
mock, as a negative control, is a small RNA that 
does not target any known gene, were 
purchased from Exiqon, Denmark. HeLa cells 
were grown to 70-80% confluence and then 
transfected with miR-SX-1 (50 or 100 nM) 
and mock miRNA or without miRNA, by 
Polyfect. After 24 h post-transfection, the cells 
were infected with HSV-1 at multiplicity of 
infection (MOI) 0.1, 1, 5 for 1 h with gentle 
shaking 15 min intervals to allow viral 
adsorption. The cells were cultured with 
serum-free DMEM at 37 °C in 5% CO2 
incubator (18). The inhibitory effect of 
miRNA on HSV-1 replication was measured 
by comparing cytopathic effect (CPE) on 
transfected cells to no transfection or mock 
after 2- days posttransfection.  
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Transfection efficacy 
HeLa cells were seeded in 24-well cell 
culture plates. At 70-80% confluency               
FAM-labeled miRNA mimic control 
5’UCACCGGGUAAUCACUUG (miRCURY 
LNA microRNA, Exiqon, Denmark) was 
transfected into HeLa cells at 50 and 100 nM 
concentrations. On 24, 48, and 72 h                     
post-transfection, the transfection efficacy was 
assessed using fluorescent microscope               
(Nikon, Japan).  
 
Plaque assays 
HeLa cells were grown in 24-well plates to 
70 to 80% confluence and then transfected 
with miR-SX1 mimics and infected with  
HSV-1 as described above and let to absorb 
for 1 h at 37 °C in 5% CO2 incubator with 
gentle shaking at 15 min intervals. Then, cells 
were overlaid with 1 mL of a 1: 1 mixture of 
Noble agar (Difco, USA) and 2 × DMEM/high 
glucose. After 48 h post-infection agarose was 
removed carefully and plates were fixed with 
10% paraformaldehyde for 15 min and stained 
with 1% crystal violet for 20 min. Plaques 
were counted and photographed. The plaque 
reduction ratio was calculated (18). 
 
Quantitative real-time polymerase chain 
reaction analysis 
HeLa cells were grown in 12-well plates to 
80 to 90% confluency and then transfected 
with various miRNA (50, 100 nM) by 
polyfect. After 24 h, cells were infected with 
HSV-1 at the indicated MOI. DNA was 
extracted from HSV-1 infected cells.             
The cells were washed three times with PBS 
and then digested in 500 µL lysis buffer              
(10 mM tris-HCL pH 7.4, 0.1 M EDTA,               
0.5% SDS). DNA was extracted from HSV-1 
infected cells by 3 times freeze and thawing 
followed by phenol-chloroform.  
The DNA was precipitated with 100% 
ethanol in the presence of 0.3 M sodium 
acetate. After washing with 70% ethanol, the 
pellet were dried and suspended in 100 µL of 
sterile tris-EDTA buffer and stored at -20° C 
(19). 
To detect the relative expression level of 
HSV-1 DNA, SYBR Green based real time 
polymerase chain reaction (RT-PCR) was 
carried out. Relative expression levels of 
HSV-1 DNA were assessed by amplification 
of viral UL47 gene.  
The primer pairs used to detect                  
UL47 were as follows: forward, 
5’GACGTACGCGATGAGATCAA3’ and 
reverse, 5’GTTACCGGATTACGGGGACT3' 
(20). Human beta-globin was used as internal 
control gene (21). All RT-PCRs were done in 
20 µL volume containing Real Q plus master 
mix green (Ampliqon, Denmark). The reaction 
conditions were 95 °C for 10  min, 40 cycles of 
95 °C for 10  s, 65 °C for 20  s, and 72 °C for 
30  s, and 72 °C for 5  min by ABI Step-one 
(Applied Biosystems, USA). Each run was 
completed with a melting curve analysis to 
confirm the specificity of the amplification. 
 
Statistical analysis  
Data are demonstrated as mean ± standard 
deviation (SD). Kolmogorov-Smirnov's test 
and based on the normal distribution of the 
data, independent sample t-test were used to 
analyze the data with SPSS, Version 20. The 
significance level was considered to be less 
than 0.05. 
 
RESULTS 
 
MiR-SX-1 effects on cell viability 
To determine the effect of miR-SX-1 on the 
viability of cells, we used MTT assay (Fig. 1). 
The viability of HeLa cells in different 
concentrations (50 and 100 nM) of miR-SX-1 
remained unchanged (P > 0.05). 
 
 
 
Fig. 1. Cell viability with miR-SX1 mimics and mock at 
different concentrations assessed by MTT assay. Each 
sample was analyzed in triplicate (P > 0.05). 
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Transfection efficacy  
The transfection efficiency, appropriate 
concentration, and optimum expression 
condition of miR-SX1 in HeLa cells were 
determined by fluorescent microscopy. As 
shown in Fig. 2, the transfection efficiency 
was up to 85% on the first day. The percentage 
of transfection was maintained about 80% up 
to 48 h after transfection but decreased 72 h 
later. 
  
MiR-SX-1 inhibits cytopathic effects of HeLa 
cells infected with HSV-1 
HeLa cells were transfected with 50 and 
100 nM concentrations of miR-SX-1 mimics 
or mock miRNA. Twenty-four h post 
transfection HeLa cells were infected with 
transfection HeLa cells were infected with 
HSV-1 at MOI of 0.1, 1, and 5 as described 
above. Cellular morphological changes were 
observed 6 and 24  h post infection by inverted 
microscope and photographed. At 6  h post-
infection, there were no obvious differences in 
cellular morphology among cells transfected 
with miR-SX-1, the mock, without miR-SX-1, 
and control cells (data not shown). Infected 
cells usually show clusters. At 24  h post-
infection, miR-SX-1 reduced CPE in a dose-
dependent manner with full inhibition at 100 
nM miR-SX1 in MOI of 1, and 5. Although, 
CPE increased clearly in HSV-1 infected cells 
alone or cells transfected with the mock 
miRNA control (Fig. 3a-3c). 
 
Fig. 2. Transfection efficiency. FAM-labeled miRNA at 100 nM was transfected into HeLa cells. The transfection 
efficiency of the miRNA was detected by fluorescent microscopy and brightfield at 24, 48, and 72 h after transfection. 
Magnification, 400×. 
 
Fig. 3. MiR-SX1 effects on HSV-1 production in HeLa cells. HeLa cells were transfected with miR-SX1 mimics at 50, 
100 nM or mock at 100 nM, followed by HSV-1 infection with MOI (a) 0.1, (b) 1, and (c) 5, 24 h post-transfection. The 
cells were imaged at 24 h post-infection. CPE clearly increased in the cells transfected with mock and HSV-1 infected 
cells alone, although CPE dramatically decreased in cells treated with miR-SX1 mimics. Magnification, 400×. miR, 
microRNA; HSV-1, herpes simplex virus type 1; CPE, cytopathic effect.  
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MiR-SX1 reduces HSV-1 titer in HeLa cells 
HeLa cells were transfected with miR-SX1 
(50 and 100 nM) followed by infecting HSV-1 
into the cells at different MOI (0.1, 1, and 5), 
after 24 h post transfection. At 24 h post-
infection, the titer of virus in miR-SX1 
transfected cells was much lower than in the 
mock and non-transfected cells (Fig. 4). The 
virus production is reduced more than 94% at 
100 nM of miR-SX-1 in MOI of 5 (P < 0.001)  
Evaluation of miR-SX1 on HSV-1 infection 
was performed by plaque assay, as a gold 
standard phenotypic method for evaluation of 
HSV-1 susceptibility to antiviral drugs (18). 
miR-SX1 at 100 nM reduced plaque numbers 
about 75, 94, and 96 % at MOI 0.1, 1, and 5, 
respectively compared with the control virus 
(Fig. 5). 
 
MiR-SX1 decreased HSV-1 genome load 
RT-PCR is reported to be a sensitive 
method for determination of antiviral 
susceptibility of HSV-1 (22). Because genome 
replication makes the virus pathogenic, the 
antiviral activity of miR-SX1 was investigated 
by quantification of the viral genome. Primers 
targeting UL 47 was used for viral 
quantification. As shown in Fig. 6, HeLa cells 
transfected with miR-SX1 at 100 nM, could 
result in a noteworthy decrease of viral DNA 
in cells compared with the virus control group 
(P < 0.001). 
 
 
 
 
Fig. 4. Virus titer in HeLa cells transfected with miR-SX1 mimcs. HeLa cells were transfected with miR-SX1 at 0, 50, 
and 100 nM  and mock RNA or without miRNA. After 24 h post-transfection, the cells were infected with HSV-1 with 
MOI (a) 0.1, (b) 1, and (c) 5. After 24 h samples were harvested for TCID50. Control group are cells without treatment 
and virus infection. TCID50 showed that treatment with miRNA mimics at 100 nM decreased the titer of the virus in 
different MOIs compared to the mock and HSV-1 infected cells, *P < 0.05 and ***P < 0.001. miR, microRNA; HSV-1, 
herpes simplex virus type 1; TCID50, 50% tissue culture infective dose ; MOI, multiplicity of infection. 
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Fig. 5. Effect of miR-SX1 on plaque formation. HeLa cells were transfected with miRNAs at specified concentration 
and infected with HSV-1 at different MOI (a, 0.1; b, 1; and c, 5). Plaques were counted 72 h later compared with the 
virus control group. Arrows indicates virus plaque. miR, microRNA; MOI, multiplicity of infection. 
 
 
 
Fig. 6. Effect of miR-SX1 on viral genome load. HeLa cells were transfected with 50 and 100 nM of miR-SX1 and 
infected with HSV-1 at MOI 0.1, 1, and 5. At 18 h post-infection the DNA was extracted and relative level of viral 
DNA was quantified. Data are analyzed as the mean of three individual experiments. Significant differences were 
observed in comparison with corresponding control group (viral group); *P < 0.05, **P < 0.01, ***P < 0.001. 
 
DISCUSSION 
 
Several studies have shown miRNAs are 
important molecules that can regulate HSV-1 
replication. Therefore, it can be concluded that 
some viral disease could be regulated or 
treated by inducing or controlling miRNAs. It 
has been demonstrated that miR-H6 encoded 
from HSV-1 genome targets ICP4 to help 
maintain latency (23). It has shown that the 
synthesized ICP4-targeting siRNA exhibits 
excellent antiviral activity in inhibiting HSV-1 
replication in retinal pigment epithelial cells 
(18). Also, siRNAs targeting VP5 (HSV-1 
major capsid protein) confers excellent 
antiviral activity by inhibiting HSV-1 
replication in cells (24). Because the effect of 
the novel miR-SX1 on HSV-1 has not yet been 
investigated, we focused to study the effect of 
miR-SX1 mimics on HSV-1 replication in 
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HeLa cells. As we have shown, less CPE and 
lower viral titer were detected in HSV-1 
infected cells with miR-SX1 compared with 
mock-treated cells or untreated controls. We 
found that miR-SX1 mimics inhibits HSV-1 
CPE in HeLa cells. Similar results were 
reported by Umbach et al. and Duan et al. who 
found that viral miR-H6 inhibits expression of 
ICP4 in 293 cells and HCE (23,25). 
Cytotoxicity levels of miR-SX1 were very low 
even at high concentrations (data not shown). 
In addition, inhibitory effects were related to 
the concentration of the miRNA, such that 100 
nM miRNA was, to some degree, more 
effective than 50 nM (Fig. 4). The 
concentration dependency of inhibitory effects 
of miRNA have also been reported in other 
virus infections. The inhibitory effect of miR-
SX1 was investigated with different MOI of 
HSV-1. We showed that at different MOI, 
CPE decreased dramatically, while 
multinucleated giant cells could be seen in 
non-transfected infected cells. The course of 
infection will be really different between lower 
and higher MOI where at higher MOI the 
effect of HSV-1 infected cells can be seen 
while it will be difficult to see the effects 
derived from reinfections virus produced in 
cells infecting others. We found that miR-SX1 
could inhibit infecting of other cells at low 
MOI (Fig. 3). In our present study, we used 
HeLa cells to study the effect of miR-SX1 
mimics on replication of HSV-1. Recently, it 
has shown that these novel miRNAs, except 
miR-SX5, are expressed in low levels in HeLa 
cells (26). Therefore, the phenotypic effect of 
mimic miRNA-SX1 on HSV-1 infected HeLa 
cells is directly related to the exogenously 
transfected miRNA. The reduction of viral 
yields by RT-PCR validates the antiviral 
activity of miR-SX1 in HeLa cells. Targets of 
miRNA have a significant role in viral 
pathogenesis and host defense mechanisms. 
The potential putative virus targeted by miR-
SX1 were identified by scanning of viral 
reference sequences from NCBI (13). The 
alignment binding position nucleotides (start 
position 66169 and 68339) would be UL30 
gene which is involved in the DNA 
replication. One possible reason is that the 
inhibition of DNA replication might be a 
strong candidate for the antiviral effect of 
miR-SX1 in the host cells. This is the first time 
any phenotypic effect of this novel miRNA is 
examined. More studies on functional aspects 
of the novel miR-SX1 such as identification of 
its key molecular targets would have a greater 
effect on our understanding of the antiviral 
mechanism of hsa-miR-7704 (-SX1).  
 
CONCLUSION 
 
We provided evidences for antiviral effect 
of novel hsa-miR-7704 (-SX1) on HSV-1 
replication in HeLa cells. The identification of 
antiviral miRNAs provides beneficial evidence 
to develop our therapeutic strategies to control 
virus infections. Further studies are warranted 
to characterize the effect of this miRNA on 
various viral infections and cell types to define 
the role of miRNA on viral pathogenicity and 
host defense. 
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